Comparing the current results to its competitors, Bullfrog Ai Holdings Inc reported Revenue increase in the 2 quarter 2026 by 547.64 % year on year. The sales growth was above Bullfrog Ai Holdings Inc 's competitors' average revenue growth of 5.77 %, achieved in the same quarter.
Bullfrog Ai Holdings Inc , slower than the average decrease reported by the company's competitors of -61.04 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -61.04 %
Bullfrog Ai Holdings Inc 's Comment on Competition and Industry Peers
The pharmaceutical and biotechnology industries, particularly in immuno-oncology, neuroscience, and rare disease segments, are highly competitive. Competitors include major pharmaceutical companies, specialty pharmaceutical firms, biotechnology companies, academic institutions, governmental agencies, and public and private research organizations. Some competitors possess greater financial resources and expertise in research and development, manufacturing, clinical trials, regulatory approvals, and marketing. Industry consolidation through mergers and acquisitions may concentrate resources among fewer competitors. Competition also occurs in recruiting qualified personnel, establishing clinical trial sites, patient registration, and acquiring complementary technologies. Smaller or early-stage companies can be significant competitors, often through collaborations with larger companies. Key competitive factors for product candidates include efficacy, safety, convenience, price, and the effectiveness of companion diagnostics.
October 9, 2024
AI-Driven Breakthrough in Liver Disease Treatment: BullFrog AI s BF-114 Shows Promising Results In an era of rapid technological advancements, the intersection of artificial intelligence and medicine is yielding groundbreaking innovations. BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW), a pioneering technology-enabled drug development company, recently announced a significant milestone in the quest for effective liver disease treatments. Their drug candidate, BF-114, supported by cutting-edge AI and machine learning technologies, has shown promising results in addressing complex liver disorders, as published in the peer-reviewed journal Cell Reports .Liver diseases represent a major global health burden, ...
July 25, 2024
In a groundbreaking collaborative effort, BullFrog AI and the Lieber Institute for Brain Development unveiled significant insights into the mechanisms underlying bipolar disorder. This partnership not only advances our understanding of this complex mental health condition but also sets the stage for potential therapeutic innovations. As investigations progress, discussions regarding drug target discovery deals with prospective pharmaceutical partners have commenced, signaling BullFrog AI s strategic move into the biotech realm. Unpacking the Findings BullFrog AI, known for its proprietary artificial intelligence platforms, has joined forces with the Lieber Institute, a premier research institute dedicated to...
January 17, 2024
In a groundbreaking collaboration, BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) and the Lieber Institute for Brain Development (LIBD) have made early strides in revolutionizing our understanding and treatment of psychiatric disorders. Leveraging artificial intelligence (AI) and machine learning technologies, BullFrog AI has successfully stratified brain expression data, offering unparalleled insights into these complex mental health conditions.The innovative partnership between BullFrog AI, a technology-enabled drug development company, and LIBD has the potential to transform the landscape of psychiatric research and therapeutic approaches. The initial findings from this global alliance signal a signific...
Biohaven Ltd operates as a pharmaceutical company that focuses on discovering and developing therapies for neurological diseases and rare disorders. Their business model revolves around conducting extensive research and clinical trials to bring innovative treatments to market. By collaborating with healthcare professionals, regulatory agencies, and investors, Biohaven aims to improve the lives of patients suffering from these conditions and provide a significant return on investment for stakeholders.
Insmed Inc operates as a biopharmaceutical company focused on developing novel therapies for serious and rare diseases. The company's business model revolves around discovering, developing, and commercializing innovative therapies to address significant unmet medical needs. Insmed Inc's efforts primarily center around leveraging its expertise in biologics and advanced drug delivery technologies to improve the lives of patients with rare pulmonary diseases.
Iterum Therapeutics Plc is a pharmaceutical company that focuses on the research, development, and commercialization of innovative anti-infectives for the treatment of serious and life-threatening infections. They aim to address unmet medical needs in this space by advancing their product candidates through clinical trials and ultimately bringing them to market.
Jazz Pharmaceuticals Plc is a biopharmaceutical company focused on developing and commercializing innovative therapies for a range of medical conditions. Their business model revolves around conducting extensive research and development to identify novel molecules and compounds that can address unmet medical needs. By leveraging strategic partnerships, acquisitions, and licensing agreements, they aim to bring these therapies to market and provide valuable treatment options to patients worldwide.
Sources:
Bullfrog Ai Holdings Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Bullfrog Ai Holdings Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
